Literature DB >> 15110580

Marginal donors in liver transplantation.

G Tisone1, T M Manzia, S Zazza, N De Liguori Carino, C Ciceroni, I De Luca, L Toti, C U Casciani.   

Abstract

Marginal liver donor criteria included the following: obesity (weight >100 Kg or BMI >27), age >50 years; macrovesicular steatosis >50%; intensive care unit stay >4 days; prolonged hypotensive episodes of >1 hour, and <60 mm Hg with high inotropic drug use (dopamine, [DPM] > 14 microg/kg per minute); cold ischemia time >14 hours, peak serum sodium >155 mEq/L; sepsis, viral infections, and alcoholism; high levels of bilirubin, ALT, and AST, or extrahepatic neoplasia. Between August 1992 and May 2003, we performed 251 liver transplants in 241 patients of whom 155 are presently alive. We used 124 (49.4%) standard donors and 127 (50.6%) marginal donors. Among the group that received a standard donor, 81 (65.3%) are still alive. Among recipients of organs from marginal donors. 81 (63.8%) are still alive. We also assessed the quality of donors according to the severity of recipient disease. For standard donors these outcomes were 61.5% for UNOS 1, 37.5% for UNOS 2A, 73.2% for UNOS 2B, and 80% for UNOS 3 for marginal donors they were 46.1% for UNOS 1, 53.6% for UNOS 2A, 70.7% for UNOS 2B, and 63.6% for UNOS 3. Among the patients who received a liver from a donor >60 years old, there were no survivors in UNOS 1 and 2A, but there were good results in groups 2B and 3. These results suggest there is no difference between marginal and standard donors, even in sick patients, with the exception of donor age.

Entities:  

Mesh:

Year:  2004        PMID: 15110580     DOI: 10.1016/j.transproceed.2004.02.022

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Deceased donor liver transplant: Experience from a public sector hospital in India.

Authors:  Viniyendra Pamecha; Deeplaxmi Purushottam Borle; Senthil Kumar; Kishore Gurumoorthy Subramanya Bharathy; Piyush Kumar Sinha; Shridhar Vasantrao Sasturkar; Vibuti Sharma; Chandra Kant Pandey; Shiv Kumar Sarin
Journal:  Indian J Gastroenterol       Date:  2017-11-29

2.  Donation after cardiac death: the University of Wisconsin experience with liver transplantation.

Authors:  David P Foley; Luis A Fernandez; Glen Leverson; L Thomas Chin; Nancy Krieger; Jeffery T Cooper; Brian D Shames; Yolanda T Becker; Jon S Odorico; Stuart J Knechtle; Hans W Sollinger; Munci Kalayoglu; Anthony M D'Alessandro
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

3.  Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017.

Authors:  Angus W Jeffrey; Luc Delriviere; Geoff McCaughan; Michael Crawford; Peter Angus; Robert Jones; Graeme A Macdonald; Jonathan Fawcett; Alan Wigg; John Chen; Ed Gane; Stephen Munn; Gary P Jeffrey
Journal:  Transplant Direct       Date:  2019-07-23

Review 4.  The future of organ perfusion and re-conditioning.

Authors:  Annemarie Weissenbacher; Georgios Vrakas; David Nasralla; Carlo D L Ceresa
Journal:  Transpl Int       Date:  2019-05-08       Impact factor: 3.782

5.  5-Aminolevulinate improves metabolic recovery and cell survival of the liver following cold preservation.

Authors:  Xiaomei Zhang; Liang Chen; Wei Liu; Juan Shen; Haobin Sun; Jinliang Liang; Guo Lv; Guihua Chen; Yang Yang; Jingxing Ou
Journal:  Theranostics       Date:  2022-03-21       Impact factor: 11.600

6.  Trends in Outcomes for Marginal Allografts in Liver Transplant.

Authors:  Theodore Zhang; Jordan Dunson; Fasiha Kanwal; Nhu Thao Nguyen Galvan; John M Vierling; Christine O'Mahony; John A Goss; Abbas Rana
Journal:  JAMA Surg       Date:  2020-08-05       Impact factor: 14.766

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.